Avantor went into this earnings day with a quietly improving share chart, up over the past week, month and quarter, yet the stock dropped about 3.7% to roughly US$13.86 by the close. That gap between recent gains and the sudden pullback is the story. The company delivered Q2 revenue of US$1.69b and adjusted earnings per share of US$0.21, while free cash flow stayed strong enough for more debt paydown and leverage around 3.3x. For a life sciences supplier still working through a turnaround, this quarter was about balance sheet credibility as much as profit progress.

Love Avantor’s solid free cash flow and debt paydown but concerned that a turnaround story can still be bumpy? You can compare this setup with companies that already pair strong balance sheets and consistent cash generation using our list of solid balance sheet and fundamentals stocks (46 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$1,692.3m vs. US$1,683.4m (roughly flat year on year)
• Net Income, Q2 2026 vs. Q2 2025: US$38.1m vs. US$64.7m (declined about 41%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.056 vs. US$0.095 (declined about 41%)
• Trailing Twelve Month Net Income, Q2 2026 vs. Q2 2025 TTM: loss of US$578m vs. profit of US$687.4m (moved from profit into loss over the last year)

Prefer clean charts over squinting at another wall of earnings tables and balance sheet figures for Avantor? Get a clear visual read on Avantor’s valuation in the full company report for Avantor.

Evaluating Avantor’s Turnaround Milestones

The bullish argument on Avantor is that the Revival program will convert a pressured distributor into a higher quality, cash generative life sciences platform. Q2 gives some concrete proof points. VWR, the core distribution arm that had been losing share, returned to organic growth of 1.7% with broad based gains across large global accounts and smaller customers using the refreshed vwr.com. That aligns with the claim that commercial fixes, pricing tools and better onboarding are starting to stick.

On the higher margin side, BMP is still in organic decline, yet order intake grew at a double digit rate and book to bill ran at 1.1x. That is the type of pipeline recovery bulls want to see for bioprocessing and medtech. Combined with US$152m of free cash flow and leverage at 3.3x with debt paydown, Q2 hits several of the balance sheet and operational milestones the turnaround narrative requires.

Reveal where the surface looks calm but the multi year models for Avantor start to diverge from today’s price and ask what the street is quietly building into revenue and earnings over the next few years with the analyst estimates for Avantor.

Avantor Bears Still See Structural Weakness, Not Just Noise

The bearish view on Avantor centers on structurally shrinking real revenue, margin compression and a fragile bioprocessing engine. Q2 gives those critics fresh ammunition. Organic revenue was slightly negative and trailing twelve month net income swung from a profit of US$687.4m to a loss of US$578m. That shift lines up with worries that headline stability can mask pressure on real earnings power. Net income for the quarter fell about 41% year on year even as VWR returned to modest organic growth. This suggests mix and cost inflation are still biting.

In bioprocessing and medtech, BMP revenue continued to decline organically despite strong orders and a 1.1x book to bill ratio. Management highlighted sequential margin improvement, yet consolidated adjusted EBITDA margin sat at 15%, and the stock fell about 3.7% on the day. For now, bears can argue that early Revival wins have not yet disproved concerns about structurally lower profitability.

After Avantor’s shift from trailing profits to a trailing loss, are the visible issues the whole story or just early signals? Review our independent risk analysis for Avantor which shows 1 important warning sign

Stay Ahead With Simply Wall St

If Avantor’s mix of solid free cash flow, leverage at 3.3x and a recent swing from trailing profits to a trailing loss has your attention, register for free with Simply Wall St and add it to a Watchlist to watch how the share price tracks against fair value and earnings trends. If you already hold Avantor, use the Portfolio Command Center to cut through noise so you only see the most important changes to fundamentals, valuation and risks. For a longer term view, tap into crowd insights and different investor angles on Avantor through the Community and see how others are interpreting the same data. This way you spot potential catalysts and red flags early and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Avantor Today?

Fresh ideas move first while the crowd hesitates. Catch potential breakout stories and building momentum before they stop flying under the radar for now. Act now.

• Spot potential income workhorses and shortlist companies with hefty yields using our curated set of 8 dividend fortresses before the best entry points are caught by faster investors.
• Hunt for possible upside in sectors powering AI growth and sort through 56 AI infrastructure stocks while the strongest operators are still flying under most radars.
• Track the changing energy story and scan 90 nuclear energy infrastructure stocks before more investors catch on to which infrastructure stocks are quietly building momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.